Omalizumab Retreatment of Patients with Chronic Idiopathic Urticaria/Spontaneous Urticaria (CIU/CS) Following Return of Symptoms: Primary Results of the Optima Study

Main Article Content

Gordon Sussman
Jacques Hebert
Wayne Gulliver
Charles Lynde
William H Yang
Olivier Chambenoit
Antonio Vieira
Frederica DeTakaosy
Lenka Rihakova

Keywords

urticaria, omalizumab, chronic urticaria, biologic therapy

Abstract

Abstract not available

 

Disclosures: Study sponsored by Novartis.

 

Copyright 2018 SKIN